Significance of the parkin gene and protein in understanding Parkinson’s disease
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Mutations in the parkin gene cause autosomal recessive inherited juvenile parkinsonism (ARJP) and account for the majority of cases of inherited Parkinson’s disease (PD) of young onset (<45 years of age). Patients with parkin mutations commonly have atypical clinical features such as dystonia at onset, hyper-reflexia, diurnal fluctuations, and sleep benefit; however, parkin mutation patients with both typical PD symptoms and older age of onset have been identified. Parkin is a ubiquitin protein ligase (E3), a component in the pathway that attaches ubiquitin to specific proteins, designating them for degradation by the proteasome. Several substrates for parkin have been identified (CDCrel-1, o-glycosylated α-synuclein, parkin associated endothelin-like cell receptor, and synphilin). The role of these substrates in the pathogenesis of ARJP is under active study. Most patients with parkin mutations lack Lewy bodies, suggesting that functional parkin is involved in the formation of these highly ubiquitinated inclusions. Furthermore, the recognition that parkin mutations can lead to a disorder clinically similar to sporadic PD, but presumably lacking Lewy bodies, calls into question the necessity of Lewy bodies for the diagnosis of PD and nigral cell death. Studies of parkin are increasing the focus on the role of the ubiquitin-proteasome system in the pathogenesis of both familial and sporadic PD.
- Kitada T, Asakawa S, Hattori N, et al.: Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392:605–608. CrossRef
- Mori H, Kondo T, Yokochi M, et al.: Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 1998, 51:890–892.
- Takahashi H, Ohama E, Suzuki S, et al.: Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 1994, 44:437–441.
- Hilker R, Klein C, Ghaemi M, et al.: Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 2001, 49:367–376. CrossRef
- Broussolle E, Lucking CB, Ginovart N, et al.: [18 F]-dopa PET study in patients with juvenile-onset PD and parkin gene mutations. Neurology 2000, 55:877–879.
- Hayashi S, Wakabayashi K, Ishikawa A, et al.: An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Disord 2000, 15:884–888. CrossRef
- Portman AT, Giladi N, Leenders JL, et al.: The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations. Neurology 2001, 56:1759–1762.
- Farrer M, Chan P, Chen R, et al.: Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001, 50:293–300. CrossRef
- Polymeropoulos MH, Lavedan C, Leroy E, et al.: Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997, 276:2045–2047. CrossRef
- Spillantini MG, Schmidt ML, Lee VM, et al.: Alpha-synuclein in Lewy bodies. Nature 1997, 388:839–840. CrossRef
- Voges D, Zwickl P, Baumeister W: The 26S proteasome: a molecular machine designed for controlled proteolysis. Ann Rev Biochem 1999, 68:1015–1068. CrossRef
- Lorick KL, Jensen JP, Fang S, et al.: RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci U S A 1999, 96:11364–11369. The authors are first to describe the general importance of RING finger-containing protein in a large class of E3 ubiquitin ligases and to experimentally demonstrate that many of these RING-containing E3s will auto-ubiquitinate. CrossRef
- Moynihan TP, Ardley HC, Nuber U, et al.: The ubiquitinconjugating enzymes UbcH7 and UbcH8 interact with RING finger/IBR motif-containing domains of HHARI and H7-AP1. J Biol Chem 1999, 274:30963–30968. This research was the first to demonstrate E3 ubiquitin ligase function for a RING-IBR-RING protein and was important in indicating likely E3 activity for parkin. CrossRef
- Aguilera M, Oliveros M, Martinez-Padron M, Barbas JA, Ferrus A: Ariadne-1: a vital Drosophila gene is required in development and defines a new conserved family of ring-finger proteins. Genetics 2000, 155:1231–1244. The researchers identify ubiquitin ligase function for Drosophila ariadne and describe the Drosophila phenotype for this RING-IBR-RING protein, which is similar to parkin.
- Shimura H, Hattori N, Kubo S, et al.: Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000, 25:302–305. This paper offers the first demonstration that parkin is an E3 ubiquitin-protein ligase and put forth the hypothesis that accumulation of a parkin substrate may be toxic and account for dopaminergic cell death in autosomal recessive inherited juvenile parkinsonism. CrossRef
- Shimura H, Hattori N, Kubo S, et al.: Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol 1999, 45:668–672. CrossRef
- Zhang Y, Gao J, Chung KK, et al.: Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci U S A 2000, 97:13354–13359. This is the first identification of a substrate for parkin E3 ubiquitinligase activity. CDC-rel1 was identified based on yeast two-hybrid approach. The signficance of this potential parkin substrate remains undetermined. CrossRef
- Beites CL, Xie H, Bowser R, Trimble WS: The septin CDCrel-1 binds syntaxin and inhibits exocytosis. Nat Neurosci 1999, 2:434–439. CrossRef
- Shimura H, Schlossmacher MG, Hattori N, et al.: Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease. Science 2001, 293:263–269. This paper is important for identifying a form of α-synuclein as a substrate for parkin and is the first to demonstrate the accumulation of a candidate substrate in the autosomal recessive inherited juvenile parkinsonism (ARJP) brain. It provides a theoretical framework for the relationship between α-synuclein containing Lewy bodies and parkin loss of function in ARJP. Additionally, a novel, potentially pathogenic, form of α-synuclein is first biochemically described in this research. CrossRef
- Imai Y, Soda M, Inoue H, et al.: An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 2001, 105:891–902. This work is central to the mechanisms of parkin in autosomal recessive inherited juvenile parkinsonism by stablishing a new substrate, parkin associated endothelin-like receptor, and emphasizing the role of parkin in endosplasmic reticulum stress response. CrossRef
- Imai Y, Soda M, Takahashi R: Parkin suppresses unfolded protein stress-induced cell death throught Its E3 ubiquitinprotein ligase activity. J Biol Chem 2000, 270:2344–2351. This is the first research to suggest that parkin functions in the endoplasmic reticulum stress-response pathway.
- Friedlander R, Jarosch E, Urban J, Volkwein C, Sommer T: A regulatory link between ER-associated protein degradation and the unfolded-protein response. Nat Cell Biol 2000, 2:379–384. CrossRef
- Nakagawa T, Zhu H, Morishima N, et al.: Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000, 403:98–103. This work demonstrates the importance of endosplamic reticulum stress-signalling pathway and caspase 12-mediated apoptosis in neurodegenerative disease. CrossRef
- Chung KK, Zhang Y, Lim KL, et al.: Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson’s disease. Nat Med 2001, 7:1144–1150. The authors identify an important new parkin substrate, synphilin, which was already linked Lewy bodies and α-synuclein pathology. This work leads to testable hypotheses about parkin’s role in sporadic disease. CrossRef
- Fallon L, Moreau F, Croft BG, et al.: Parkin and CASK/LIN-2 Associate via a PDZ-mediated interaction and are co-localized in lipid rafts and prostsyna densities in brain. J Biol Chem 2002, 277:486–491. CrossRef
- Choi P, Ostrerova-Golts N, Sparkman D, et al.: Parkin is metabolized by the ubiquitin/proteosome system. NeuroReport 2000, 11:2635–2638. CrossRef
- Suzuki T, Park H, Kwofie MA, Lennarz WJ: Provides a link between the Png1 deglycosylating enzyme and the 26 S proteasome in yeast. J Biol Chem 2001, 276:21601–21607. CrossRef
- Wolozin B, Behl C: Mechanisms of neurodegenerative disorders: part 1: protein aggregates. Arch Neurol 2000, 57:793–796. CrossRef
- Gregori L, Hainfeld JF, Simon MN, Goldgaber D: Binding of amyloid beta protein to the 20 S proteasome. J Biol Chem 1997, 272:58–62. CrossRef
- Lam YA, Pickart CM, Alban A, et al.: Inhibition of the ubiquitin-proteasome system in Alzheimer’s disease. Proc Natl Acad Sci U S A 2000, 97:9902–9906. CrossRef
- Bence NF, Sampat RM, Kopito RR: Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552–1555. This research establishes that misfolded aggregating proteins can impair proteasome function and may lead to cell death via proteasome inhibition. It also demonstrates an important new cellular method for assessing proteasome function in living cells using a GFP-based indicator protein. CrossRef
- Fergusson J, Landon M, Lowe J, et al.: Pathological lesions of Alzheimer’s disease and dementia with Lewy bodies brains exhibit immunoreactivity to an ATPase that is a regulatory subunit of the 26S proteasome. Neurosci Lett 1996, 219:167–170. CrossRef
- McNaught KS, Jenner P: Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci Lett 2001, 297:191–194. CrossRef
- Tanaka Y, Engelender S, Igarashi S, et al.: Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet 2001, 10:919–926. CrossRef
- Cummings CJ, Mancini MA, Antalffy B, et al.: Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat Genet 1998, 19:148–154. CrossRef
- Chan HY, Warrick JM, Gray-Board GL, Paulson HL, Bonini NM: Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in drosophila. Hum Mol Genet 2000, 9:2811–2820. Demonstrates the usefulness of Drosophila as a model for neurodegenerative disease and illustrates the ablity of using this in vivo model of polyglutamine disease to delineate chaparone function as a repressor of pathogenesis. CrossRef
- Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM: Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease. Science 2002, 295:865–868. The researchers demonstrate the importance of chaparones in modulating the α-synuclein toxicity. CrossRef
- Leroy E, Boyer R, Auburger G, et al.: The ubiquitin pathway in Parkinson’s disease. Nature 1998, 395:451–452. CrossRef
- Maraganore DM, Farrer MJ, Hardy JA, et al.: Case-control study of the ubiquitin carboxy-terminal hydrolas L1 gene in Parkinson’s disease. Neurology 1999, 53:1858–1860.
- Saigoh K, Wang YL, Suh JG, et al.: Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet 1999, 23:47–51. This work is important because it demonstrated the role of ubiquitin carboxy-terminal hydrolase (UCH-L1) in a murine model of neurodegeneration and supported the relevance of the ubiquitin-proteasome pathway in Parkinson’s disease.
- Abbas N, Luckin CB, Ricard S, et al., for the French Parkinson’s Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson’s Disease: A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. Hum Mol Genet 1999, 8:567–574. The French Parkinson’s disease genetics study group and the European consortium define the range of parkin mutation-mediated disease and establishes that parkin mutation is a common basis of early-onset autosomal recessive parkinsonism worldwide. CrossRef
- Klein C, Pramstaller PP, Kis B, et al.: Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann Neurol 2000, 48:65–71. This paper showed that parkin mutations could cause typical Parkinson’s disease (PD) with older age of onset than in autosomal recessive inherited juvenile parkinsonism, helping to alleviate critisms that parkin mutations lead to a phenotype much different than sporadic PD. CrossRef
- Maruyama M, Ikeuchi T, Saito M, et al.: Novel mutations, pseudo-dominant inheritence, and possible familial affects in patients with autosomal recessive juvenile parkinsonism. Ann Neurol 2000, 48:245–250. CrossRef
- Lucking CB, Bonifati V, Periquet M, et al.: Pseudo-dominant inheritance and exon 2 triplication in a family with parkin gene mutations. Neurology 2001, 57:925–927.
- Asakawa S, Tsunematsu K, Takayanagi A, et al.: The genomic structure and promoter region of the human parkin gene. Biochem Biophys Res Commun 2001, 286:863–868. CrossRef
- Lucking CB, Durr A, Bonifanti V, et al.: Association between early-onset Parkinson’s disease and mutations in the parkin gene. French Parkinson’s Disease Genetics Study Group. N Engl Med 2000, 342:1560–1567. This is an important study on the relationship between early-onset Parkinson’s disease (PD) and parkin mutations. This research helps define a wider phenotype for parkin mutation patients than the classic autosomal recessive inherited juvenile parkinsonism presentation, and places some estimates on the frequency of parkin mutations in early-onset PD. CrossRef
- Kobayashi T, Wang M, Hattori N, et al.: Exonic deletion mutations of the Parkin gene among sporadic patients with Parkinson’s disease. Parkinsonism Relat Disord 2000, 6:129–131. CrossRef
- Periquet M, Lucking C, Vaughan J, et al.: Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from founder effects. Am J Hum Genet 2001, 68:617–626. CrossRef
- Satoh J, Kuroda Y: Association of codon 167 Ser/Asn heterozygosity in the parkin gene with sporadic Parkinson’s disease. Neuroreport 1999, 10:2735–2739. CrossRef
- Terreni L, Calabrese E, Calella AM, Forloni G, Mariani C: New mutation (R42P) of the parkin gene in the ubiquitinlike domain associated with parkinsonism. Neurology 2001, 56:463–466.
- Significance of the parkin gene and protein in understanding Parkinson’s disease
Current Neurology and Neuroscience Reports
Volume 2, Issue 4 , pp 296-302
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links